Cargando…
Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment
Metastatic castrate-resistant prostate cancer (CRPC) remains uncurable and novel therapies are needed to better treat patients. Aberrant Fibroblast Growth Factor Receptor (FGFR) signaling has been implicated in advanced prostate cancer (PCa), and FGFR1 is suggested to be a promising therapeutic targ...
Autores principales: | Ko, Juyeon, Meyer, April N., Haas, Martin, Donoghue, Daniel J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7800776/ https://www.ncbi.nlm.nih.gov/pubmed/33456711 http://dx.doi.org/10.18632/oncotarget.27859 |
Ejemplares similares
-
The Receptor Tyrosine Kinase FGFR4 Negatively Regulates NF-kappaB Signaling
por: Drafahl, Kristine A., et al.
Publicado: (2010) -
Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling
por: Nelson, Katelyn N., et al.
Publicado: (2018) -
Characterization of iPS87, a prostate cancer stem cell-like cell line
por: Assoun, Erika N., et al.
Publicado: (2020) -
FGFR-TKI resistance in cancer: current status and perspectives
por: Yue, Sitong, et al.
Publicado: (2021) -
Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
por: Terp, Mikkel G., et al.
Publicado: (2021)